Clinical Trials in SAN M. de Tucuman, Argentina
8 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Myositis
Pfizer318 enrolled147 locationsNCT05895786
Recruiting
Phase 2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative ColitisUlcerative Colitis Chronic
Eli Lilly and Company140 enrolled207 locationsNCT06598943
Recruiting
Phase 3
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
ObesityWeight Gain
Eli Lilly and Company300 enrolled75 locationsNCT06439277
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
AlopeciaSkin DiseasesAreata Alopecia+3 more
Eli Lilly and Company595 enrolled127 locationsNCT05723198
Recruiting
Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled154 locationsNCT07353931
Recruiting
Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
DermatomyositisPolymyositis
Pfizer211 enrolled24 locationsNCT06698796
Recruiting
Phase 3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Eli Lilly and Company190 enrolled82 locationsNCT03773965
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company58 enrolled55 locationsNCT04088396